BioSight Overview

  • Founded
  • 1999
Founded
  • Status
  • Private
  • Employees
  • 10
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $46M
Latest Deal Amount
  • Investors
  • 13

BioSight General Information

Description

Developer of novel peptide-based drugs intended to provide therapeutics for hematological malignancies and disorders. The company's drugs target and release therapeutic enzymes inside cancer cells to reduce systemic toxicity associated with conventional chemotherapy treatments, enabling patients to receive safe and effective treatment for life-threatening diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 3 Hayarden Street, Airport City
  • P.O.B 1083
  • Lod 7019802
  • Israel
+972 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioSight Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 02-Dec-2020 $46M 000.00 Completed Clinical Trials - Phase 2
4. Secondary Transaction - Private 15-Jun-2017 00.00 000.00 Completed Clinical Trials - Phase 2
3. Later Stage VC 16-May-2016 0000 000.00 000.00 Completed Clinical Trials - Phase 2
2. Later Stage VC 30-Jul-2008 $3.5M $3.5M Completed Clinical Trials - General
1. Early Stage VC Completed Startup
To view BioSight’s complete valuation and funding history, request access »

BioSight Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred B1 000,000 00.000000 000.00 000.00 00 000.00 00.000
Preferred B 000,000 00.000000 000.00 000.00 00 000.00 00.000
To view BioSight’s complete cap table history, request access »

BioSight Executive Team (10)

Name Title Board Seat Contact Info
Ruth Yakar Ph.D Chief Executive Officer & Board Member
Stela Gengrinovitch Ph.D Co-Founder, Chief Scientist & Chief Scientific Officer
Ehud Shoshani Vice President of Clinical affairs
Liat Flaishon Ph.D Vice President of Medical Affairs
Shoshi Tessler Ph.D Vice President of Research & Development
You’re viewing 5 of 10 executive team members. Get the full list »

BioSight Board Members (14)

Name Representing Role Since
Aaron Sasson Primera Capital (Venture Capital) Board Member 000 0000
Briggs Morrison MD Self Board Member 000 0000
Gary Gordon Ph.D Israel Biotech Fund Board Member 000 0000
Liora Ettinger Self Board Member 000 0000
Pini Orbach Ph.D Arkin Bio-Ventures Chairman 000 0000
You’re viewing 5 of 14 board members. Get the full list »

BioSight Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioSight Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioTelemetry Corporation Minority 000 0000 000000 0
Israel Biotech Fund Venture Capital Minority 000 0000 000000 0
Migdal Insurance Company Corporation Minority 000 0000 000000 0
Phoenix Insurance Company Corporation Minority 000 0000 000000 0
SBI JI Innovation Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »